NCT01993667.

Trial name or title	Acetazolamide for the prevention of high altitude illness: a comparison of dosing
Methods	Interventional
Participants	Inclusion criteria 18 years or older English or Indian speaking Mountaineers or trekkers who plan to climb Mt. McKinley or trek to Base Camp on Mt. Everest Exclusion criteria Low sodium and/or potassium blood serum levels Kidney disease or dysfunction Liver disease, dysfunction, or cirrhosis Suprarenal gland failure or dysfunction Hyperchloraemic acidoses Angle‐closure glaucoma Taking high dose aspirin (over 325 mg/day) Any reaction to sulfa drugs or acetazolamide Pregnant or lactating women
Interventions	Drug: acetazolamide
Outcomes	Prevention of acute mountain sickness as measured by the Lake Louise Score (time frame: 1 year) Side effect profile of acetazolamide (time frame: 1 year)
Starting date	March 2012
Contact information	Scott McIntosh, MD
Notes	Recruiting